MUKILTEO, Wash., Oct. 15, 2007 (PRIME NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced that Leuchemix (LCMX), Inc. has reported the publication of pre-clinical data regarding its lead oncology drug candidate LC-1 in the publication, “Blood,” which is the official journal of the American Society of Hematology. The paper details studies performed using LC-1 in Acute Myelogenous Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), and Acute Lymphoblastic Leukemia (ALL) and demonstrates the exciting potential this agent has in the treatment of hematological diseases.
